This page contains a Flash digital edition of a book.
with the new American JointCommittee on Cancer sixth edition 38. Meyerhardt J.A., Tepper J.E., Niedzwiecki D. Et al. Impact of
staging. J NatlCancer Inst 2004; 96:1420-1425. hospital procedure volume on surgical operation and long-term
18. Compton C., Fenoglio-Preiser C.M., Pettigrew N., Fielding L.P. outcomes in high-risk curatively resected rectal cancer: findings
American Joint Committee onCancer Prognostic Factors Con- from the Intergroup 0114 Study. J Clin Oncol 2004;22:166-174.
sensus Conference:Colorectal Working Group. Cancer 2000;88: 39. Sobrero A., Guglielmi A., Grossi F. et al. Mechanism of action
1739-1757. of fluoropyrimidines: relevance to the new developments in
19. Krasna M.J., Flancbaum L., Cody R.P. et al. Vascular and neu- colorectal cancer chemotherapy. Semin Oncol 2000;27(Suppl
ral invasion in colorectal carcinoma. Incidence and prognostic 10):72-77.
significance. Cancer 1988;61:1018-1023. 40. Higgins G.A., Humphrey E., Juler G. et al. Adjuvant chemo-
20. Hampel H., Frankel W.L., Martin E. et al. Screening for the therapy in the surgical treatment of large bowel cancer. Cancer
Lynch syndrome (hereditary non-polyposis colorectal cancer). N 1976;38:1461-1467.
Engl J Med 2005;352:1851-1860. 41. Higgins G.A., Donaldson R.C., Humphrey E.W. et al. Adjuvant
21. Shibata D., Reale M.A., Lavin P. et al. The DCC protein and prog- therapy for large bowel cancer: update of Veterans Administra-
nosis in colorectal cancer. N Engl J Med 1996;335:1727-1732. tion Surgical Oncology Group Trials. Surg Clin North Am 1981;
22. Hodgson D.C., Zhang W., Zaslavsky A.M. et al. Relation of hos- 61:1311-1320.
pital volume to colostomy rates and survival for patients with 42. Grossi C.E., Wolff W.I., Nealon T.F. Jr. et al. Intraluminal
rectal cancer. J Natl Cancer Inst 2003;95:708-716. fluorouracil chemotherapy adjunct to surgical procedures for
23. Wanebo H.J., Rao B., Pinsky C.M. et al. Preoperative carcino- respectable carcinoma of the colon and rectum. Surg Gynecol
embryonic antigen level as a prognostic indicator in colorectal Obstet 1977; 145:549-554.
cancer. N Engl J Med 1978;299:448-451. 43. Grage T.B., Moss S.E. Adjuvant chemotherapy in cancer of the
24. Wolmark N., Fisher B., Wieand H.S. et al. The prognostic colon and rectum: demonstration of effectiveness of prolonged
significance of preoperative carcinoembryonic antigen levels in 5-FU chemotherapy in a prospectively controlled, randomized
colorectal cancer. Results from NSABP (National Surgical Ad- trial. Surg Clin North Am 1981;61:1321-1329.
juvant Breast and Bowel Project) clinical trials. Ann Surg 1984; 44. Buyse M., Zeleniuch-Jacquotte A., Chalmers T.C. Adjuvant
199:375-382. therapy of colorectal cancer. Why we still don’t know. JAMA
25. Moertel C.G., Fleming T.R., Macdonald J.S. et al. Intergroup 1988;259:3571-3578.
study of fluorouracil plus levamisole as adjuvant therapy for 45. Taylor I., Machin D., Mullee M. Et al. A randomized controlled
stage II/Dukes’B2 colon cancer. J Clin Oncol 1995;13:2936-2943. trial of adjuvant portal vein cytotoxic perfusion in colorectal
26. Gryfe R., Kim H., Hsieh E.T. et al. Tumor microsatellite instabil- cancer. Br J Surg 1985;72:359-363.
ity and clinical outcome in young patients with colorectal can- 46. Wereldsma J.C., Bruggink E.D., Meijer W.S. et al. Adjuvant por-
cer. N Engl J Med 2000;342:69-77. tal liver infusion in colorectal cancer with 5-fluorouracil/hepa-
27. Watanabe T., Wu T.T., Catalano P.J. et al. Molecular predictors rin versus urokinase versus control. Results of a prospective
of survival after adjuvant chemotherapy for colon cancer. N Engl randomized clinical trial (colorectal adenocarcinoma trial I).
J Med 2001;344:1196-1206. Cancer 1990;65:425-432.
28. Popat S., Houlston R.S. A systematic review and meta-analy- 47. Beart R.W. Jr., Moertel C.G., Wieand H.S. et al. Adjuvant therapy
sis of the relationship between chromosome 18q genotype, DCC for resectable colorectal carcinoma with fluorouracil adminis-
status and colorectal cancer prognosis. Eur J Cancer 2005;41: tered by portal vein infusion. A study of the Mayo Clinic and the
2060-2070. North Central Cancer Treatment Group. Arch Surg 1990;125:897-
29. Swanson R.S., Compton C.C., Stewart A.K., Bland K.I. The 901.
prognosis of T3N0 colon cancer is dependent on the number of 48. Wolmark N., Rockette H., Wickerham D.L. et al. Adjuvant therapy
lymph nodes examined. Ann Surg Oncol 2003;10:65-71. of Dukes’A, B, and C adenocarcinoma of the colon with portal-vein
30. Le Voyer T.E., Sigurdson E.R., Hanlon A.L. et al. Colon cancer fluorouracil hepatic infusion: preliminary results of National Surgi-
survival is associated with increasing number of lymph nodes cal Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol
analyzed: a secondary survey of intergroup trial INT-0089. J Clin 1990;8:1466-1475.
Oncol 2003;21:2912-2919. 49. Fielding L.P., Hittinger R., Grace R.H., Fry J.S. Randomised con-
31. Berger A.C., Sigurdson E.R., LeVoyer T. et al. Colon cancer sur- trolled trial of adjuvant chemotherapy by portal vein perfusion
vival is associated with decreasing ratio of metastatic to exam- after curative resection for colorectal adenocarcinoma. Lancet
ined lymph nodes. J Clin Oncol 2005;23:8706-8712. 1992; 340:502-506.
32. Stocchi L., Nelson H., Sargent D.J. et al. Impact of surgical and 50. Long-term results of single course of adjuvant intraportal
pathologic variables in rectal cancer:a United States community chemotherapy for colorectal cancer. Swiss Group for Clinical
and cooperative group report. J Clin Oncol 2001; 19:3895-3902. Cancer Research (SAKK). Lancet 1995;345:349-353.
33. Tepper J.E., O’Connell M.J., Niedzwiecki D. Et al. Impact of num- 51. Portal vein chemotherapy for colorectal cancer: a meta-analy-
ber of nodes retrieved on outcome in patients with rectal cancer. sis of 4000 patients in 10 studies. Liver Infusion Meta-analysis
J Clin Oncol 2001;19:157-163. Group. J Natl Cancer Inst 1997;89:497-505.
34. Compton C.C., Greene F.L. The staging of colorectal cancer: 52. Bedikian A.Y., Valdivieso M., Mavligit G.M. et al. Sequential
2004 and beyond. CA Cancer J Clin 2004;54:295-308. chemoimmunotherapy of colorectal cancer: evaluation of meth-
35. Heald R.J., Moran B.J., Ryall R.D. et al. Rectal cancer: the Basing- otrexate, Baker’s Antifol and levamisole. Cancer 1978;42:2169-
stoke experience of total mesorectal excision, 1978-1997. Arch 2176.
Surg 1998; 133:894-899. 53. Buroker T.R., Moertel C.G., Fleming T.R. et al. A controlled
36. Kapiteijn E., Marijnen C.A., Nagtegaal I.D. et al. Preoperative evaluation of recent approaches to biochemical modulation or
radiotherapy combined with total mesorectal excision for re- enhancement of 5-fluorouracil therapy in colorectal carcinoma.
sectable rectal cancer. N Engl J Med 2001;345:638-646. J Clin Oncol 1985;3:1624-1631.
37. Schrag D., Cramer L.D., Bach P.B. et al. Influence of hospital 54. Windle R., Bell P.R., Shaw D. Five year results of a randomized
procedure volume on outcomes following surgery for colon can- trial of adjuvant 5-fluorouracil Adjuvant Treatment of Colorectal
cer. JAMA 2000; 284:3028-3035. Cancer 182CAA Cancer Journal for Clinicians.
pag. 32
Nr. 7 (2)/2009
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68
Produced with Yudu -